Guardant Reveal

1 clinical trials involving this therapy/drug

This is not medical advice - consult your oncologist

Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.

RecruitingUnknown phaseBreast cancerLung cancerOvarian cancerColorectal cancerGastric cancerPancreatic cancerMelanomaBladder cancerHead and neck cancerTriple negative (TNBC)HER2 positiveHormone receptor positive (HR+)Early / localized

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444ClinicalTrials.gov ↗

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.

Full details →

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.